The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids
- PMID: 38181746
- DOI: 10.1016/j.stem.2023.12.010
The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids
Abstract
Using an isogenic organoid platform to model pancreatic cancer, Duan et al. establish an important link between mutant KRAS and cholesterol metabolism and identify perhexiline maleate as a possible therapeutic to target this relationship.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.Cell Stem Cell. 2024 Jan 4;31(1):71-88.e8. doi: 10.1016/j.stem.2023.11.011. Epub 2023 Dec 26. Cell Stem Cell. 2024. PMID: 38151022 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
